Literature DB >> 26092582

Immunoglobulin G4-related diseases in the head and neck: a systematic review.

Graeme B Mulholland1, Caroline C Jeffery2, Paras Satija3, David W J Côté4.   

Abstract

BACKGROUND: Immunoglobulin G4 related disease (IgG4-RD) is a poorly understood chronic inflammatory disorder affecting the middle-aged and elderly that can present to the otolaryngologist. We aim to summarize the current literature regarding the manifestations and management of IgG4-RD in the head and neck.
METHODS: Pubmed and EMBASE were searched using the term relevant search algorithm utilizing keywords such as: IgG4 related disease, head and neck, orbit, salivary glands, sialadenitis, Kuttner, angiocentric eosinophilic fibrosis, submandibular, lacrimal, thyroid, dacryoadenitis, nasal, sinus, and Mikulicz's. Reference lists were searched for identification of relevant studies. Case reports, original research and review articles published in English from 1964 to 2014 whose major topic was IgG4-RD affecting the head and neck were included. Data regarding patient demographics, presentation, histopathology, management and treatment outcomes of IgG4-RD were extracted. Level of evidence was also assessed and data were pooled where possible. Three independent reviewers screened eligible studies; extracted relevant data and discrepancies were resolved by consensus, where applicable. Descriptive and comparative statistics were performed.
RESULTS: Fourty-three articles met our inclusion criteria. IgG4-RD most often presents as a mass lesion in the head and neck region. Common diagnostic features include: (1) elevated serum IgG4 level, (2) marked infiltration of exocrine glands by IgG4-positive plasma cells with fibrosis, and (3) marked improvement with corticosteroid therapy and additional immunosuppressive therapy in corticosteroid refractory cases. Early diagnosis and involvement of rheumatology is important in management.
CONCLUSIONS: IgG4-RD is a challenging non-surgical disease that has multiple manifestations in the head and neck. It must be distinguished from various mimics including malignancy, systemic diseases, and infectious. Otolaryngology-Head and Neck surgeons should be aware of this condition and its management.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26092582      PMCID: PMC4482182          DOI: 10.1186/s40463-015-0071-9

Source DB:  PubMed          Journal:  J Otolaryngol Head Neck Surg        ISSN: 1916-0208


Introduction

Immunoglobulin G4 – related disease (IgG4-RD) is a newly described fibroinflammatory condition that often presents as a tumefactive lesion that can affect nearly every organ system. IgG4-RD was first recognized after a connection between elevated serum IgG4 levels and inflammatory mass lesions in the pancreas causing autoimmune pancreatitis was made by Hamano et al. in 2001 [1]. An initial consensus statement regarding diagnosis of IgG4-RD was developed by Deshpande et al. at the first international symposium for IgG4-RD held in October of 2011 [2]. After the pancreas, the head and neck region is second most common site for presentation of IgG4-RD. More, a number of historically perplexing pseudotumor disorders have been attributed to IgG4-RD; these include Mikulicz’s disease, Küttner’s tumor and Reidel’s thyroiditis [3]. The exact etiology of IgG4-RD is unknown and no known role of the IgG4 molecule itself has been identified. It is postulated that the inflammatory and fibrotic processes that drives IgG4-RD are propagated by a combination of Th2 cells and regulatory T cells (Treg cells) [4]. This is contrary to most autoimmune disorders where polarized T helper 1 (Th1) and/or Th17 subsets are responsible for the inflammatory process [5]. Histologically, the hallmark findings for IgG4-RD include lymphoplasmacytic infiltration, storiform fibrosis, obliterative phlebitis, and mild to moderate tissue eosinophilia [6]. However, the exact histological findings vary greatly depending on the tissue affected and clinical presentation. Currently, the histologic diagnosis of IgG4-RD is based primarily on IgG4 positive to IgG containing cell ratio and the number of IgG4 positive cells per high powered field, a ratio of IgG4 to IgG that is higher than 50 % and 30 IgG4-positive cells per high-power field is considered to be highly suggestive of IgG4-RD [6]. Currently, the literature proposes that IgG4-RD could be both over and under recognised [7]. This study aims to examine the various presentations of IgG4-RD in the head and neck, and present the management and outcomes reported in the literature.

Material and methods

This systematic review was performed using the following search strategy and study selection criteria.

Literature search strategy

The databases PubMed (1966-December 2014) and Embase (1988-December 2014) were searched using an algorithm designed from an extensive list of relevant search terms (see Appendix A for Pubmed and Embase search algorithms). We included all original studies, case reports, case series, and reviews. Relevant articles and abstracts were selected and reviewed and the reference lists from these sources and recent review articles were also reviewed for additional publications.

Study selection

Three independent reviewers screened the identified articles (GBM, CCJ and PS). Relevant articles were obtained and reviewed in full. Discrepancies were resolved by consensus amongst the reviewers. The inclusion criteria comprised of all original clinical studies, case series and case reports of histologically confirmed IgG4-RD in the head and neck. Histologic diagnosis of IgG4-RD required identification of >10 IgG4 positive plasma cells per high powered field, IgG4 + plasma cell to IgG containing cell ratio 40 % or greater, and characteristic finding of fibrosis, sclerosis and phlebitis. Articles were excluded on the basis of biopsy information not being from a head and neck site, insufficient histologic information, inability to extract head and neck specific information and narrative review and expert opinions.

Data extraction

The information gathered for each study included study design, country of publication and number of patients. Where possible, patient-specific data was extracted, including age at presentation, duration and nature of symptoms. Specifically, we collected data regarding head and neck manifestations, laboratory and histologic findings as well as specific treatments and outcome information.

Statistical analysis

Basic statistical analysis, including descriptive statistics was performed using Excel (Version 19.0, Microsoft ®).

Results

We initially identified 1592 articles through a combination of literature search and citation review. After reviewing abstracts, 247 articles of interest were identified. Three authors independently reviewed the articles and 43 articles met inclusion criteria (Fig. 1). Of the 43 articles, 21 case reports and 5 large case series (greater than 15 patients) were included (Table 1). A large proportion of articles were from Japan (41.9 %), contributing 86.6 % of the total individual cases (Table 1).
Fig. 1

Flow chart of studies obtained through literature search, eligible and excluded (Uploaded separately as per submission instructions)

Table 1

Country of origin and characteristics of included articles

N (Articles)%N (Individual Cases)%
Total number of studies43484
Case Reports2148.8214.3
Small Case Series1739.510722.1
Large Case Series511.635673.6
Country of OriginNorth America1023.3275.6
Canada12.310.2
USA920.9265.4
Asia2251.242988.6
Japan1841.941986.6
Hong Kong24.781.7
Taiwan12.310.2
Singapore12.310.2
Oceania614.071.4
Australia511.661.2
New Zealand12.310.2
Europe49.3204.1
United Kingdom12.310.2
Netherlands12.3122.5
Czech Republic12.361.2
Switzerland12.310.2
South America12.310.2
Brazil12.310.2
Flow chart of studies obtained through literature search, eligible and excluded (Uploaded separately as per submission instructions) Country of origin and characteristics of included articles Four hundred and eighty-four patients were identified with an average patient age of 60.4 years (Table 2). Table 3 shows the proportion of patients presenting by various sites in the head and neck. Cervical lymphadenopathy was document in 22 cases. Many of the patients also had involvement of other organ systems at the time of presentation, including 56 patients with lymphadenopathy outside of the head and neck (see Table 3). All patients had tissue biopsy from head and neck sites confirming the diagnosis of IgG4-RD. Confirmatory laboratory investigations was included where documented. The laboratory and histologic findings of patients indentified in the literature are summarized in Table 4.
Table 2

Basic patient demographics

Total number of Patients484
Average Age (years)60.4
Percent Males47.5 %
Table 3

Systemic and head and neck manifestations

Head & Neck ManifestationsSiteSubsiten%
Total presentations730
Orbit38452.6
Lacrimal Gland13618.6
Extra Ocular Muscles91.2
Optic Nerve50.7
Salivary Glands16222.2
Submandibular Gland10714.7
Parotid Gland294.0
Sublingual Gland10.1
Minor Salivary Gland10.1
Thyroid314.2
Facial Skin60.8
Trigeminal Nerve10.1
Cervical Lymphadenopathy223.0
Non Head & Neck ManifestationsSiten%
Other Organ Involvement689.3
Mediastinal/Pelvic Lymphadenopathy567.7
Table 4

Laboratory and histologic findings

Mean Values
Serum IgG4 (mg/dL)702.9
Serum IgG (mg/dL)2445.0
IgG4 + ve Plasma Cells / HPF69.8
IgG4 + ve Cells / IgG Containing Cells48.0 %
Basic patient demographics Systemic and head and neck manifestations Laboratory and histologic findings Treatment information was available for 26.7 % of patients. Patients were treated with surgical excision, radiotherapy, corticosteroids with or without adjunct medical treatment, or some combination of treatment modalities. The distribution of patients in terms of treatment(s) received and their outcomes are summarized in Table 5. Treatment outcomes were known in 99 patients. Of these, full remission was seen in 90.0 % in response to medical treatment. Corticosteroids treatment alone was effective for 67 patients (67.7 %) in achieving full remission.
Table 5

Treatment and progress

Treatments Received by Patients (N = 129)n%
Surgical Management Alone1511.6
Combined Surgical and Medical Management43.1
Medical Management Alone10782.9
Treatment with Corticosteroidsa Alone8465.1
Treatment with Corticosteroids and One Additional Immunosuppressive Agentb 1612.4
Treatment with Corticosteroids and Multiple Additional Immunosuppressive Agents107.8
Treatment Outcomes (N = 99)n%
Full Remission with Medical Treatment8990.0
Full Remission with Corticosteroids Alone6767.7
Intolerance, Relapse with Taper, or Treatment Failure with Corticosteroids as First Line3232.3
Full Remission with Addition of Single Immunosuppressive Agent to Corticosteroids1414.1
Full Remission with Addition of Multiple Immunosuppressive Agents to Corticosteroids88.1
Remission Not Achieved99.1

aCorticosteroids included: prednisolone, methylprednisone and triamcinolone injections

bAdditional immunosuppressive agents included: rituximab, methotrexate, azathioprine, mycophenolate mofetil, tamoxifen, 6-mercaptopurine, chlorambucil, cyclosporine and cyclopohosphamide

Treatment and progress aCorticosteroids included: prednisolone, methylprednisone and triamcinolone injections bAdditional immunosuppressive agents included: rituximab, methotrexate, azathioprine, mycophenolate mofetil, tamoxifen, 6-mercaptopurine, chlorambucil, cyclosporine and cyclopohosphamide

Discussion

This is the first systematic review of IgG4-RD presentation in the head and neck. Our study demonstrates a strong propensity for IgG4-RD to present in the head and neck region. We included 43 articles containing 484 patients. The most common site of presentation was the orbit, followed by the submandibular gland – with many patients having presentations in multiple head and neck and distant sites. Treatment information was also collected, showing that majority of patients receiving corticosteroids responded very well to treatment. The vast majority of the included cases were from Asia (429 of 484 or 88.6 %) and more specifically Japan (419 of 484 or 86.6 %). Indeed, much of the literature on IgG4-RD originates from Japan [8]. This poses the question of whether IgG4-RD more prevalent in the Japanese population or simply better recognized? While IgG4-RD was first recognized in Japan, it is increasingly recognized throughout the rest of the world [7]. While cases have been reported on every continent and in most ethnic groups, reports from countries outside of Asia comprise smaller case series. This highlights the emerging status of IgG4-RD in the literature and likely an increase in reporting in the future. While systemic presentations of IgG4-RD favor males over females with a reported ratio of 2.8-3.5:1, our study demonstrates an almost 1 to 1 ratio of head and neck manifestations [6, 9, 10]. Orbital involvement was most common subsite in the head and neck and the majority of the orbital presentations (219 cases) came from a single study [11]. Common orbital manifestations included periorbital swelling, eyelid swelling, and proptosis. Salivary gland and lacrimal gland involvement were very common and included submandibular, parotid gland, and lacrimal gland enlargement, infiltration, and formation of pseudotumours. Lymphadenopathy was a particularly common presentation in the head and neck. This was often associated with lymphadenopathy elsewhere including the mediastinum and retroperitoneum. More rare forms of head and neck involvement included the thyroid gland in the form of Riedel’s Thyroiditis as well as sinonasal and airway manifestations. Few patients in our series received surgical excision alone. The majority cases received some form of medical management comprising of high-dose corticosteroids. Patients had excellent response to medical therapy alone with full remission rate of 90 %. A consensus statement from 17 referral centres in Japan developed a treatment regime of 0.6 mg/Kg prednisolone for 2 to 4 weeks with a taper over 3 to 6 months and a low daily dose for 3 years. Importantly, this regime was developed for treatment of autoimmune pancreatitis, where consequences of not treating are associated with significant morbidity and mortality [12]. However, other authors advocate watchful waiting with observation over a number of years as an acceptable treatment approach [13]. Based on our results, surgery remains most useful for obtaining histologic diagnosis. Strict selection criteria was used in article selection. Histologic diagnosis was based on IgG4 + ve cells/ HPF and the IgG4 + ve/IgG ratio. This is considered the most rigorous definition of IgG4-RD [4, 6]. However, since biopsy from the head and neck was one of the criteria, there are likely many studies of IgG4-RD in the head and neck that were excluded as biopsies were obtained from other tissues. Unfortunately, there is a paucity of high quality publications on this topic. The majority of the information available exists in the form of case reports and small case series, which comprise of low level of evidence. There are also inconsistencies in reporting key information. Many studies were excluded due to insufficient information (152 or 74.5 %) or a lack of basic histologic information; articles lacking IgG4+ cell/HPF or the IgG4+/IgG ratio --items critical to confirming the presence of IgG4-RD-- were excluded.

Conclusions

Due to the numerous potential manifestations of IgG4-RD in the head and neck, it is crucial for otolaryngologists to be aware of this condition. A high index of suspicious is required particularly in the setting of patients who present with recurrent salivary and lacrimal gland swelling, lymphadenopathy, along with fibroinflammatory systemic involvement. This disease process remains under recognized and poorly understood. Future studies are necessary to better understand the pathophysiology and natural history of this disease.
  55 in total

1.  Chronic sclerosing dacryoadenitis: part of the spectrum of IgG4-related Sclerosing disease?

Authors:  Wah Cheuk; Hunter K L Yuen; John K C Chan
Journal:  Am J Surg Pathol       Date:  2007-04       Impact factor: 6.394

2.  Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells.

Authors:  Ingunn M Stromnes; Lauren M Cerretti; Denny Liggitt; Robert A Harris; Joan M Goverman
Journal:  Nat Med       Date:  2008-02-17       Impact factor: 53.440

Review 3.  IgG4-related disease.

Authors:  Vinay S Mahajan; Hamid Mattoo; Vikram Deshpande; Shiv S Pillai; John H Stone
Journal:  Annu Rev Pathol       Date:  2013-10-02       Impact factor: 23.472

Review 4.  Lacrimal gland sparing IgG4-related disease in the orbit.

Authors:  Tanya T Khan; Shams K Halat; Adham B Al Hariri
Journal:  Ocul Immunol Inflamm       Date:  2013-03-12       Impact factor: 3.070

5.  High serum IgG4 concentrations in patients with sclerosing pancreatitis.

Authors:  H Hamano; S Kawa; A Horiuchi; H Unno; N Furuya; T Akamatsu; M Fukushima; T Nikaido; K Nakayama; N Usuda; K Kiyosawa
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

Review 6.  The clinical spectrum of IgG4-related disease.

Authors:  Pilar Brito-Zerón; Manuel Ramos-Casals; Xavier Bosch; John H Stone
Journal:  Autoimmun Rev       Date:  2014-08-22       Impact factor: 9.754

7.  Unilateral eyelid mass as an unusual presentation of ocular adnexal IgG4-related inflammation.

Authors:  Fabricio L da Fonseca; Renata de Iracema Pulcheri Ramos; Patricia P de Lima; Ariel B Nogueira; Suzana Matayoshi
Journal:  Cornea       Date:  2013-04       Impact factor: 2.651

8.  Eosinophilic angiocentric fibrosis is a form of IgG4-related systemic disease.

Authors:  Vikram Deshpande; Arezou Khosroshahi; Gunnlaugur P Nielsen; Daniel L Hamilos; John H Stone
Journal:  Am J Surg Pathol       Date:  2011-05       Impact factor: 6.394

Review 9.  Immunoglobulin G4-related sclerosing sialadenitis: report of two cases and review of the literature.

Authors:  Takahiro Abe; Tsuyoshi Sato; Yasuhisa Tomaru; Yasuaki Sakata; Shoichiro Kokabu; Naoko Hori; Akio Kobayashi; Tetsuya Yoda
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2009-10

10.  Standard steroid treatment for autoimmune pancreatitis.

Authors:  T Kamisawa; T Shimosegawa; K Okazaki; T Nishino; H Watanabe; A Kanno; F Okumura; T Nishikawa; K Kobayashi; T Ichiya; H Takatori; K Yamakita; K Kubota; H Hamano; K Okamura; K Hirano; T Ito; S B H Ko; M Omata
Journal:  Gut       Date:  2009-04-26       Impact factor: 23.059

View more
  19 in total

1.  Immunoglobulin G4-related disease of the paranasal sinuses.

Authors:  Anthony Bashyam; Sidhartha Nagala; Fawzia Tahir; Showkat Mirza
Journal:  BMJ Case Rep       Date:  2018-05-07

Review 2.  Ear and Temporal Bone Pathology: Neural, Sclerosing and Myofibroblastic Lesions.

Authors:  A N Flaman; J K Wasserman; D H Gravel; B M Purgina
Journal:  Head Neck Pathol       Date:  2018-08-01

Review 3.  [IgG4-associated diseases].

Authors:  M Diller; K Evert; M Fleck
Journal:  Z Rheumatol       Date:  2016-08       Impact factor: 1.372

4.  Regional Differences following Partial Salivary Gland Resection.

Authors:  K J O'Keefe; K A DeSantis; A L Altrieth; D A Nelson; E Z M Taroc; A R Stabell; M T Pham; M Larsen
Journal:  J Dent Res       Date:  2019-11-25       Impact factor: 6.116

5.  IgG4-related orbitopathy as an important differential diagnosis of advanced silent sinus syndrome.

Authors:  M Jurkov; H Olze; F Klauschen; E Bertelmann; U Schneider; P Arens
Journal:  HNO       Date:  2020-01       Impact factor: 1.284

6.  IgG4-related intracranial disease.

Authors:  Shahine Goulam-Houssein; Jeffrey L Grenville; Katerina Mastrocostas; David G Munoz; Amy Lin; Aditya Bharatha; Paraskevi A Vlachou
Journal:  Neuroradiol J       Date:  2018-10-15

Review 7.  T Cell Roles and Activity in Chronic Sclerosing Sialadenitis as IgG4-Related Disease: Current Concepts in Immunopathogenesis.

Authors:  Hazim Mahmoud Ibrahem
Journal:  Autoimmune Dis       Date:  2022-06-20

8.  Immunoglobulin G4-Related Disease Presented as Recurrent Otitis Media and Mixed Hearing Loss Treated With Cyclophosphamide and Rituximab: A Case Report.

Authors:  Shao San; Chia-der Lin; Sheng-Ta Tsai; Chao-Chun Lin; Po-Chang Wu
Journal:  Arch Rheumatol       Date:  2018-11-30       Impact factor: 1.472

Review 9.  Rare Diseases of the Orbit.

Authors:  Ulrich Kisser; Jens Heichel; Alexander Glien
Journal:  Laryngorhinootologie       Date:  2021-04-30       Impact factor: 1.057

10.  Case of IgG4 orbitopathy's remarkable response to oral corticosteroid therapy.

Authors:  Neelima Balakrishnan; Rachna Meel; Deepsekhar Das
Journal:  BMJ Case Rep       Date:  2020-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.